OTCMKTS:CLXPF

Cybin Stock Forecast, Price & News

$1.34
+0.02 (+1.52 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.24
Now: $1.34▼
$1.36
50-Day Range
$0.96
MA: $1.24▼
$1.60
52-Week Range
$0.49
Now: $1.34▼
$2.24
Volume127,809 shs
Average Volume449,630 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
Cybin logo

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CLXPF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.cybin.com
Phone416 567 4675
Employees6
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Headlines

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates - StreetInsider.com
April 7, 2021 |  streetinsider.com
Music May Play a Critical Role in Psychedelic Therapy Sessions - Baystreet.ca
April 6, 2021 |  baystreet.ca
With US FDA Support and Breakthroughs, Psilocybin a Step Closer to Legalization - Baystreet.ca
March 31, 2021 |  baystreet.ca
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Appoints New Management Positions, Focused on Development and Clinical Operations - StreetInsider.com
March 30, 2021 |  streetinsider.com
Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe
March 30, 2021 |  finance.yahoo.com
Cybin Inc. (OTCMKTS:CLXPF) Short Interest Up 101.7% in March
March 29, 2021 |  americanbankingnews.com
Mycology Interest on the Rise as Researchers Unearth More Benefits of Functional Mushroom Products - Baystreet.ca
March 27, 2021 |  baystreet.ca
Psyched: Compass' New Patents, Cure Extends DEA License, Andrew Yang Supports Psilocybin in NYC - Yahoo Finance
March 27, 2021 |  finance.yahoo.com
NetworkNewsAudio – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Poised to Profit as Investor Interest in Psychedelic Therapeutics Market Increases - StreetInsider.com
March 27, 2021 |  streetinsider.com
Cybin Inc. (NEO: CYBN) in Prime Position as Interest in Psychedelic Medicine Surges - Yahoo Finance
March 27, 2021 |  finance.yahoo.com
Cybin Inc. (NEO: CYBN) at Forefront of Psychedelic Revolution - Yahoo Finance
March 27, 2021 |  finance.yahoo.com
Cybin Inc. (NEO: CYBN) at Forefront of Psychedelic Revolution
March 26, 2021 |  finance.yahoo.com
Catalent Signs Drug Development Agreement with Cybin Inc for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
March 22, 2021 |  finance.yahoo.com
Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
March 22, 2021 |  finance.yahoo.com
Cybin Progresses Two Psychedelic Investigational New Drug ("IND") Candidates and Announces Completion of Its 20th Pre-Clinical Study
March 17, 2021 |  finance.yahoo.com
Cybin to Present at the Oppenheimer 31st Annual Healthcare Conference
March 16, 2021 |  finance.yahoo.com
With Recent Advancements, North America Is Expected To Dominate Psychedelic Drugs Market
March 9, 2021 |  finanznachrichten.de
Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition
March 9, 2021 |  finance.yahoo.com
Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on March 8, 2021
March 8, 2021 |  finance.yahoo.com
Cybin Inc. Announces Uplisting to OTCQB Venture Market
March 3, 2021 |  finance.yahoo.com
See More Headlines

MarketRank™

Overall MarketRank™

1.00 out of 5 stars

Medical Sector

1043rd out of 2,010 stocks

Biotechnology Industry

43rd out of 143 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$1.34
+0.02 (+1.52 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLXPF News and Ratings via Email

Sign-up to receive the latest news and ratings for CLXPF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cybin (OTCMKTS:CLXPF) Frequently Asked Questions

Is Cybin a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cybin in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cybin stock.
View analyst ratings for Cybin or view top-rated stocks.

What stocks does MarketBeat like better than Cybin?

Wall Street analysts have given Cybin a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cybin wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cybin?

Cybin saw a increase in short interest in March. As of March 15th, there was short interest totaling 119,200 shares, an increase of 101.7% from the February 28th total of 59,100 shares. Based on an average trading volume of 591,500 shares, the short-interest ratio is currently 0.2 days.
View Cybin's Short Interest.

Who are Cybin's key executives?

Cybin's management team includes the following people:
  • Mr. Eric So L.L.B., LLB, Co-Founder, Pres & Exec. Chairman (Age 45)
  • Mr. Douglas L. Drysdale, Chief Exec. Officer (Age 51)
  • Mr. Paul Glavine, Co-Founder, COO & Director (Age 31)
  • Mr. John Kanakis, Co-Founder & Sr. VP of Bus. Devel. (Age 40)
  • Mr. Greg Cavers, Chief Financial Officer (Age 50)
  • Dr. Alex L. Nivorozhkin Ph.D., Chief Scientific Officer (Age 61)
  • Mr. Gabriel Fahel, Chief Legal Officer (Age 45)
  • Sara Brittany Somerset, Chief Communications Officers
  • Lori Challenger, Chief of Staff
  • James Andrews, Chief Cultivation & Extraction Officer

Who are some of Cybin's key competitors?

Some companies that are related to Cybin include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Achilles Therapeutics plc American Depositary Shares (ACHL), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ) and Algernon Pharmaceuticals (AGNPF).
View all of CLXPF's competitors.

What is Cybin's stock symbol?

Cybin trades on the OTCMKTS under the ticker symbol "CLXPF."

How do I buy shares of Cybin?

Shares of CLXPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cybin's stock price today?

One share of CLXPF stock can currently be purchased for approximately $1.34.

How many employees does Cybin have?

Cybin employs 6 workers across the globe.

What is Cybin's official website?

The official website for Cybin is www.cybin.com.

How can I contact Cybin?

The company can be reached via phone at 416 567 4675.


This page was last updated on 4/11/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.